October 10, 2016 10:46 AM EDT
News Briefing

#ES­MO16: Boehringer drug flops on OS end­point; Medi­vir re­or­ga­nizes, cuts staff

Shehla Shakoor

Managing Director

Fresh on the heels of an em­bar­rass­ing set­back with a lethal can­cer drug in-li­censed from Han­mi, Boehringer In­gel­heim re­port­ed over the week­end that nintedanib …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times